

## THE NATIONAL AGRICULTURAL DEVELOPMENT COMPANY (NADEC)

(A SAUDI JOINT STOCK COMPANY)

CONDENSED INTERIM FINANCIAL STATEMENTS AND INDEPENDENT AUDITOR'S REVIEW REPORT FOR THE THREE MONTH AND NINE MONTH PERIODS ENDED

30 SEPTEMBER 2021

### THE NATIONAL AGRICULTURAL DEVELOPMENT COMPANY (NADEC) (A SAUDI JOINT STOCK COMPANY)

#### **INDEX**

	PAGES
Independent Auditor's Report on Review of Condensed Interim Financial Statements	1-2
Condensed Statement of Financial Position as at 30 September 2021	3
Condensed Statement of Profit or Loss for the three month and nine month periods ended 30 September 2021	4
Condensed Statement of Comprehensive Income for the three month and nine month periods ended 30 September 2021	5
Condensed Statement of Changes in Shareholders' Equity for the nine month period ended 30 September 2021	6
Condensed Statement of Cash flows for the nine month period ended 30 September 2021	7
Notes to the Condensed Interim Financial Statements for the nine month period ended 30 September 2021	8-14



#### **KPMG Professional Services**

Riyadh Front, Airport Road P. O. Box 92876 Riyadh 11663 Kingdom of Saudi Arabia Headquarter

Commercial Registration No 1010425494

كي بي إم جي للاستشارات المهنية

واجهة الرياض، طريق المطار صندوق بريد ۹۲۸۷۰ الرياض ۱۱۲۲۳ المملكة العربية السعودية المركز الرئيسي

سجل تجاري رقم ١٠١٠٤٢٥٤٩٤

# Independent auditor's report on review of condensed interim financial statements

To the Shareholders of National Agricultural Development Company

#### Introduction

We have reviewed the accompanying 30 September 2021 condensed interim financial statements of National Agricultural Development Company – A Saudi Joint Stock Company ("the Company") which comprises:

- the condensed statement of financial position as at 30 September 2021;
- the condensed statement of profit or loss for the three-month and nine-month periods ended 30 September 2021;
- the condensed statement of comprehensive income for the three-month and nine-month periods ended 30 September 2021;
- the condensed statement of changes in shareholders' equity for the nine-month period ended 30 September 2021;
- the condensed statement of cash flows for the nine-month period ended 30 September 2021; and
- the notes to the condensed interim financial statements.

Management is responsible for the preparation and presentation of these condensed interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed interim financial statements based on our review.

#### Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



### Independent auditor's report on review of condensed interim financial statements

To the Shareholders of National Agricultural Development Company (continued)

Lic No. 46

TPMG Professional S

#### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 September 2021 condensed interim financial statements of National Agricultural Development Company are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

KPM@Professional Services

Khalil Ibrahim Al Sedais License No. 371

Riyadh on 18 Rabi' al-Awwal 1443 H Corresponding to 24 October 2021

2



		30-Sep-21	31-Dec-20
	Note	SAR (Unaudited)	SAR (Audited)
Assets	Hote	(Ollaudited)	(Addited)
Non-Current Assets			
Property, Plant and Equipment	9	1,894,267,212	1,963,125,942
Right of Use Assets		72,432,506	58,562,699
Capital Work in Progress		109,830,987	112,185,675
Biological Assets		684,574,573	625,491,645
Intangible Assets		19,249,325	8,060,361
Equity Investment at FVOCI	11	7,629,000	7,629,000
Total Non-Current Assets		2,787,983,603	2,775,055,322
Current Assets		2), 0, 1, 00, 000	2,110,000,022
Biological Assets		38,416,697	27,689,189
Inventory		527,489,054	536,562,512
Biological Assets - Available for Sale		37,176,977	25,112,448
Trade Receivables and Other Receivables		340,557,704	325,927,480
Prepayments	10	318,568,723	116,578,737
Cash and Bank Balances		89,704,657	68,713,854
Total Current Assets		1,351,913,812	1,100,584,220
Total Assets		4,139,897,415	3,875,639,542
Shareholders' Equity and Liabilities		= 4,133,037,413	3,073,033,342
Shareholders' Equity			
Share Capital	6	1.016.400.000	1 015 100 000
Share Premium	0	1,016,400,000	1,016,400,000
Statutory Reserve		78,719	78,719
Other Reserves		184,238,643	184,238,643
Retained Earnings		22,641,853 247,149,166	22,641,853
Total Shareholders' Equity			254,919,030
Non-Current Liabilities		1,470,508,381	1,478,278,245
Murabaha Loans and Borrowings	7	1 140 404 000	000 074 075
Lease Liabilities	,	1,149,404,885	880,974,358
Deferred Income		45,879,528	29,982,682
Employee Benefits Obligation		5,237,307	5,642,608
Total Non-Current Liabilities		160,529,659	165,619,617
Current Liabilities		1,361,051,379	1,082,219,265
Trade and Other Payables		700 700 450	
Murabaha Loans and Borrowings - Short term	7	790,730,453	606,083,653
Murabaha Loans and Borrowings - Current Portion	7	197,769,153	291,064,937
Lease Liabilities	,	221,570,035	318,693,328
Dividend Payables		28,309,894	32,776,779
Provision for Zakat		32,873,514	33,130,736
Total Current Liabilities		37,084,606	33,392,599
Total Liabilities		1,308,337,655	1,315,142,032
Total Shareholders' Equity and Liabilities		2,669,389,034	2,397,361,297
Total Shareholders Equity and Liabilities		4,139,897,415	3,875,639,542
The accompanying notes 1 to 12 and 1	( al		

The accompanying notes 1 to 12 are an integral part of these condensed interim financial statements

The condensed interim financial statements appearing on pages 8 to 14 were approved by the Board of Directors and were signed on its behalf by

Asimakopoulos Georgios Chief Financial Officer Steen Hadsbjerg Chief Executive Officer

# The National Agricultural Development Company (NADEC) A Saudi Joint Stock Company Condensed Statement of Profit or Loss For the three month and nine month periods ended 30 September 2021



Revenue         8         591,437,086         587,229,361         1,665,092,712         1,754,440,076           Cost of Sales         (413,021,112)         (404,362,537)         (1,148,861,948)         (1,157,468,392)           Gross Profit         178,415,974         182,866,824         516,230,764         596,971,684           Selling and Marketing Expenses         (122,477,891)         (138,967,747)         (362,516,199)         (417,311,358)           General and Administrative Expenses         (32,124,158)         (31,369,182)         (93,372,591)         (89,816,318)           Impairment Losses on Trade Receivables         (1,314,791)         (2,520,247)         (5,630,032)         (10,724,770)           Other (Expenses) & Income – net         (9,287,999)         (1,198,605)         (33,154,040)         107,901,017           Impairment losses on Property, Plant and Equipment         13,211,135         (35,077,762)         21,557,902         143,131,450           Operating Profit/ (Loss)         13,211,135         (35,077,762)         21,557,902         143,131,450           Net gain on Derivative financial instruments         (8,497,135)         (8,604,143)         (24,799,763)         (34,243,013)           Finance cost         (8,497,135)         (8,604,143)         (24,799,763)         (34,243,013)		Note	Three month period ended 30 Sep 2021 SAR (Unaudited)	Three month period ended 30 Sep 2020 SAR (Unaudited)	Nine month period ended 30 Sep 2021 SAR (Unaudited)	Nine month period ended 30 Sep 2020 SAR (Unaudited)
Cost of Sales Gross Profit Selling and Marketing Expenses General and Administrative Expenses General and Administrative Expenses General and Administrative Expenses General and Administrative Expenses Impairment Losses on Trade Receivables Other (Expenses) & Income – net Impairment losses on Property, Plant and Equipment Operating Profit/ (Loss) Net gain on Derivative financial instruments Finance cost Profit / (Loss) before Zakat Zakat Profit / (Loss) for the period  Earnings/ (Loss) per share based on the Profit/ (Loss) per share based on the Profit/ (Loss) for the period attributable to ordinary shareholders  Rasic and Diluxed  178,415,974 182,866,824 516,230,764 596,971,684 59		8	591,437,086	587,229,361	1,665,092,712	1,754,440,076
Selling and Marketing Expenses General and Administrative Expenses General and Administrative Expenses Impairment Losses on Trade Receivables Other (Expenses) & Income – net Impairment losses on Property, Plant and Equipment Operating Profit/ (Loss) Net gain on Derivative financial instruments Finance cost Profit / (Loss) before Zakat Zakat Profit / (Loss) for the period  Earnings/ (Loss) per share based on the Profit/ (Loss) for the period attributable to ordinary shareholders  Basic and Dilyted  I 122,477,891 (138,967,747) (362,516,199) (417,311,358) (417,311,358) (32,124,158) (31,369,182) (93,372,591) (89,816,318) (1,314,791) (2,520,247) (5,630,032) (10,724,770) (1,198,605) (33,154,040) 107,901,017 (1,	Cost of Sales		(413,021,112)	(404,362,537)	(1,148,861,948)	
Selling and Marketing Expenses General and Administrative Expenses General and Administrative Expenses Impairment Losses on Trade Receivables Other (Expenses) & Income – net Impairment losses on Property, Plant and Equipment Operating Profit/ (Loss) Net gain on Derivative financial instruments Finance cost Profit / (Loss) before Zakat Zakat Profit / (Loss) for the period  Earnings/ (Loss) per share based on the Profit/ (Loss) for the period attributable to ordinary shareholders  Rate and Diluted  (122,477,891) (138,967,747) (362,516,199) (417,311,358) (31,369,182) (93,372,591) (89,816,318) (10,724,770) (10,724,770) (10,724,770) (10,724,770) (11,98,605) (33,154,040) 107,901,017 (10,901,017) (10,901,017) (11,98,605) (33,154,040) 107,901,017 (11,98,605) (33,154,040) 107,901,017 (12,502,0247) (43,888,805)  - (43,888,805) - (43,888,805) - (43,888,805)  -			178,415,974	182,866,824	516,230,764	
Impairment Losses on Trade Receivables			(122,477,891)	(138,967,747)	(362,516,199)	
Other (Expenses) & Income – net			-	(31,369,182)	(93,372,591)	(89,816,318)
Impairment losses on Property, Plant and Equipment			(1,314,791)	(2,520,247)	(5,630,032)	(10,724,770)
Equipment - (43,888,805) - (43,888,805)  Operating Profit / (Loss)  Net gain on Derivative financial instruments  Finance cost (8,497,135) (8,604,143) (24,799,763) (34,243,013)  Profit / (Loss) before Zakat (1,500,000) (1,227,927) (4,528,003) (4,321,839)  Profit / (Loss) for the period (44,893,915) (7,769,864) 104,919,791  Earnings / (Loss) per share based on the Profit / (Loss) for the period attributable to ordinary shareholders			(9,287,999)	(1,198,605)	(33,154,040)	107,901,017
Net gain on Derivative financial instruments  Finance cost  Profit / (Loss) before Zakat  Zakat  Profit / (Loss) for the period  Earnings/ (Loss) per share based on the Profit/ (Loss) for the period attributable to ordinary shareholders  Positive financial instruments  - 15,917  - 353,193  (34,243,013)  (24,799,763)  (34,243,013)  (4,321,839)  (1,500,000)  (1,227,927)  (4,528,003)  (4,321,839)  (7,769,864)  104,919,791				(43,888,805)		(43,888,805)
Net gain on Derivative financial instruments  Finance cost  Profit / (Loss) before Zakat  Zakat  Profit / (Loss) for the period  Earnings/ (Loss) per share based on the Profit / (Loss) for the period attributable to ordinary shareholders  Positive financial instruments  (8,497,135) (8,604,143) (24,799,763) (34,243,013)  (4,321,839) (4,321,839) (4,321,839)  (7,769,864) 104,919,791			13,211,135	(35,077,762)	21,557,902	143,131,450
Profit / (Loss) before Zakat  Zakat  Profit / (Loss) for the period  Earnings/ (Loss) per share based on the  Profit / (Loss) for the period attributable to ordinary shareholders  Resign and Diluted	instruments		-	15,917	•	
Profit / (Loss) before Zakat  Zakat  Profit / (Loss) for the period  Earnings/ (Loss) per share based on the  Profit / (Loss) for the period attributable  to ordinary shareholders  Basic and Diluted			(8,497,135)	(8,604,143)	(24,799,763)	(34,243,013)
Profit / (Loss) for the period  3,214,000 (44,893,915) (7,769,864) 104,919,791  Earnings/ (Loss) per share based on the Profit/ (Loss) for the period attributable to ordinary shareholders  Basic and Diluted			4,714,000	(43,665,988)	(3,241,861)	
Earnings/ (Loss) per share based on the Profit/ (Loss) for the period attributable to ordinary shareholders  Basic and Diluted			(1,500,000)	(1,227,927)	(4,528,003)	(4,321,839)
Profit/ (Loss) for the period attributable to ordinary shareholders  Basic and Diluted	Profit / (Loss) for the period	1	3,214,000	(44,893,915)	(7,769,864)	104,919,791
Basic and Diluted 5 0.03 (0.44) (0.08) 1.03	Profit/ (Loss) for the period attributable					
	Basic and Diluted	5	0.03	(0.44)	(0.08)	1.03

The accompanying notes 1 to 12 are an integral part of these condensed interim financial Statements
The condensed interim financial statements appearing on pages 3 to 14 were approved by the Board of Directors and
were signed on its behalf by

Asimakopoulos Georgios Chief Financial Officer

Steen Had bjerg Chief Executive Officer





	Three month period ended 30 Sep 2021 SAR (Unaudited)	Three month period ended 30 Sep 2020 SAR (Unaudited)	Nine month period ended 30 Sep 2021 SAR (Unaudited)	Nine month period ended 30 Sep 2020 SAR (Unaudited)
Profit / (Loss) for the period	3,214,000	(44,893,915)	(7,769,864)	104,919,791
items that will not be reclassified to Profit or Loss				
Re-measurement of Defined Benefit Obligation	-	-	-	-
Movement in Equity Investment at Fair Value through Other Comprehensive Income (FVOCI)	-	-		-
Total Items that will not be reclassified to Profit or		•		1
Loss				
Total other comprehensive income	-	•	<u>.</u>	•
Total Comprehensive Income/ (Loss) for the period	3,214,000	(44,893,915)	(7,769,864)	104,919,791

The accompanying notes 1 to 12 are an integral part of these condensed interim financial statements

The condensed interim financial statements appearing on pages 3 to 14 were approved by the Board of Directors and were signed on its behalf by

Asimakopoulos Georgios Chief Financial Officer Steen Haddbjerg Chief Executive Officer



The National Agricultural Development Company (NADEC)
A Saudi Joint Stock Company
Condensed Statement of Changes in Shareholders' Equity for the nine month period ended 30 Sep 2021

Total Shareholders' Equity	1,478,278,245	(7,769,864)	1,470,508,381	1,440,478,144	104,919,791	104,919,791	140,679	1,545,538,614
Retained Earnings	254,919,030	(7,769,864)	247,149,166	392,167,953 1,	104,919,791	104,919,791	(169,338,040)	327,749,704
Other Reserves SAR	22,641,853	.	22,641,853	20,637,006			1	20,637,006
Statutory Reserve	184,238,643		184,238,643	180,673,185			ŧ	180,673,185
Share premium	78,719		78,719	•	1 (		78,719	78,719
Share Capital	1,016,400,000		1,016,400,000	847,000,000	4 4	1	169,400,000	1,016,400,000
	Balance at 1 January 2021 (Audited)	Loss for the period Other comprehensive income for the period Total Comprehensive Loss for the period	Balance at 30 Sep 2021 (Unaudited)	Balance at 1 January 2020 (Audited)	Profit for the period Other comprehensive income for the period	Total Comprehensive Income for the period Transactions with shareholders	Issue of Bonus Shares	Balance at 30 Sep 2020 (Unaudited)

The condensed interim financial statements appearing on pages 3 to 14 were approved by the Board of Directors and were signed on its behalf by The accompanying notes 1 to 12 are an integral part of these condensed interim financial statements

Asimakopoulos Georgios Chief Financial Officer

Steen Hadsbjerg Chief Executive Officer

Abdulaziz Saleh Alrebdi Chairman 9

## The National Agricultural Development Company (NADEC) A Saudi Joint Stock Company Condensed Statement of Cash Flows for the nine month period ended 30 Sep 2021



Period ended 30		Nine month	Nine month
Cash flows from Operating Activities   (Loss) / Profit for the period   (7,69,864)   (104,919,791   Adjustments for   (17,69,864)   (19,802,152   12,615,766   (19,802,152   12,615,766   (19,802,152   12,615,766   (19,802,152   12,615,766   (19,802,152   12,615,766   (19,802,152   12,615,766   (19,802,152   12,615,766   (19,802,152   12,615,767   (19,802,152   12,615,76		period ended	period ended 30
Cash flows from Operating Activities   (Unaudited)   (Un		30 Sep 2021	Sep 2020
Cash flows from Operating Activities   (10x9) Profit for the period   (7,769,864)   104,919,791   Adjustments for   104,919,791   Adjustments for   17,8972,611   196,615,766   19,802,152   21,024,990   21,024,990   21,024,990   21,024,990   22,067,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,667,491   24,585,621   2,697,990   22,415,470   20,697,990   22,415,470   20,697,990   23,817,259   20,727,770   10,727,77		SAR	SAR
Closs  Profit for the period   104,919,791   104,919,791   104,919,791   104,919,791   104,919,791   104,919,791   104,919,791   196,615,766   196,615,767		(Unaudited)	(Unaudited)
Adjustments for Depreciation - Property Plant and Equipment and Biological Assets 178,972,611 196,615,766 Depreciation - Right of Use Assets 19,802,152 21,024,090 Amortization 4,885,621 2,667,491 2,681,680 4,528,603 4,321,839 Deferred income (405,301) (405,666) Employee Benefits Obligation 21,415,470 20,697,990 Impairment Losses on Trade Receivables 5,630,032 10,724,770 Inventory Provision movement, net 2,250,000 23,817,259 Unrealized loss on Derivatives financial instruments 2,4799,763 34,243,013 Income from Government grant (Net) 24,799,763 34,243,013 Income from Government grant (Net) 279,655,622 362,833,402 Assets 25,847,135 11,717,317 Impairment losses on Property, Plant and Equipment 279,655,622 362,833,402 Assets 10,002 Assets 10,003 Asse			
Depreciation - Property Plant and Equipment and Biological Assets   178,972,611   196,615,766		(7,769,864)	104,919,791
Depreciation - Right of Use Assets   19,802,152   21,024,090   A,785,621   2,667,491   Zakat Expense   4,528,003			
Amortization 4,585,621 2,667,491  Zakat Expense 4,528,003 4,321,839  Deferred income (405,301) (405,666)  Employee Benefits Obligation 21,415,470 20,697,990  Impairment Losses on Trade Receivables 5,680,032 10,724,770  Impairment Losses on Trade Receivables 5,680,032 10,724,770  Impairment Losses on Trade Receivables 5,680,032 10,724,770  Unrealized loss on Derivatives financial instruments 7 406,403  Finance Cost 1 4,799,763 34,243,013  Income from Government grant (Net) 24,799,763 34,243,013  Income from Government grant (Net) 24,799,763 34,243,013  Income from Government grant (Net) 25,847,135 11,717,317  Impairment losses on Property, Plant and Equipment 279,655,622 362,833,402  Changes in 1 279,655,622 362,833,402  Changes in 1 (5,241,071) (51,094,926)  Biological Assets - Available for Sale (5,241,071) (51,094,926)  Biological Assets 1 (10,727,508) 5,589,097  Trade Receivables, Prepayments and Other Receivables (222,250,242) (66,864,138)  Trade and Other Payables 226,083,601 337,168,259  Zakat Paid (83,5996) (1,00,642)  Employee Benefits Paid (83,5996) (1,00,642)  Employee Benefits Paid (83,5996) (1,00,642)  Ret cash from Operating Activities 198,742,177 320,745,412  Cash flows from Investing Activities 24,046,646,646,646,646,646,646,646,646,64		178,972,611	196,615,766
2		19,802,152	21,024,090
Deferred income		4,585,621	2,667,491
Employee Benefits Obligation 21,415,470 20,697,990 Impairment Losses on Trade Receivables 5,630,032 10,724,770 Impairment Losses on Trade Receivables 5,630,032 10,724,770 20,697,259 Unrealized loss on Derivatives financial instruments 2,250,000 23,817,259 Unrealized loss on Derivatives financial instruments 406,403 24,799,763 34,243,013 Income from Government grant (Net) 24,799,763 34,243,013 Impairment Goster of Control of C	,	4,528,003	4,321,839
Impairment Losses on Trade Receivables 5,530,032 10,724,770 Inventory Provision movement, net 2,250,000 23,817,259 406,403 Finance Cost 24,799,763 34,243,013 Income from Government grant (Net) (111,805,466) (111,		(405,301)	(405,666)
Inventory Provision movement, net		21,415,470	20,697,990
Unrealized loss on Derivatives financial instruments         -         406,403           Finance Cost         24,799,763         34,243,013           Income from Government grant (Net)         -         (111,805,466)           Loss on sale of Property Plant and Equipment and Biological Assets         25,847,135         11,717,317           Impairment losses on Property, Plant and Equipment         279,655,622         362,833,402           Changes in         Inventory and Biological Assets - Available for Sale         (5,241,071)         (51,094,926)           Biological Assets         1(10,727,508)         5,589,097           Trade Receivables, Prepayments and Other Receivables         (222,250,242)         (66,864,138)           Trade and Other Payables         184,646,800         86,704,824           Employee Benefits Paid         (835,996)         (1,010,642)           Employee Benefits Paid         (835,996)         (15,412,205)           Net cash from Operating Activities         198,742,177         320,745,412           Cash flows from Investing Activities         198,742,177         320,745,412           Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets         59,100,302         40,527,075           Net cash Used in Investing Activities         208,463,841         (142,929,747)           C		5,630,032	10,724,770
Finance Cost   24,799,763   34,243,013   Income from Government grant (Net)   - (111,805,466)   Loss on sale of Property Plant and Equipment and Biological Assets   25,847,135   11,717,317   Impairment losses on Property, Plant and Equipment   - 43,888,805   279,655,622   362,833,402		2,250,000	23,817,259
Income from Government grant (Net)  Loss on sale of Property Plant and Equipment and Biological Assets  Loss on sale of Property Plant and Equipment  Display 1,177,317  Impairment losses on Property, Plant and Equipment  Changes in  Inventory and Biological Assets - Available for Sale  Biological Assets  Trade Receivables, Prepayments and Other Receivables  Trade and Other Payables  Assets  Trade Receivables, Prepayments and Other Receivables  Employee Benefits Paid  (883,996)  (1,010,642)  Employee Benefits Paid  (883,996)  (10,010,642)  (183,456,822)  Proceeds from Investing Activities  (208,463,841)  (183,456,822)  Proceeds from Financing Activities  (208,463,841)  (183,456,822)  Employee Benefits Paid  (208,463,841)  (183,456,822)		•	406,403
Loss on sale of Property Plant and Equipment and Biological Assets   25,847,135   11,717,317   Impairment losses on Property, Plant and Equipment   279,655,622   362,833,402   362,832,932   362,833,402   362,833,402   362,832,932   362,833,402   362,832,933   362,832,932,933   362,832,932,933   362,832,932,933   362,832,932,932,932,933   362,832,932,932,932,933		24,799,763	34,243,013
Impairment losses on Property, Plant and Equipment   279,655,622   362,833,402			(111,805,466)
Changes in         279,655,622         362,833,402           Inventory and Biological Assets - Available for Sale         (5,241,071)         (51,094,926)           Biological Assets         (10,727,508)         5,589,097           Trade Receivables, Prepayments and Other Receivables         (222,250,242)         (66,864,138)           Trade and Other Payables         184,646,800         86,704,824           Zakat Paid         (835,996)         (1,010,642)           Employee Benefits Paid         (26,505,428)         (15,412,205)           Net cash from Operating Activities         198,742,177         320,745,412           Cash flows from Investing Activities         267,564,143)         (183,456,822)           Assets         59,100,302         40,527,075           Net cash Used in Investing Activities         (208,463,841)         (142,929,747)           Cash flows from Financing Activities         (208,463,841)         (142,929,747)           Repayment of Murabaha Loans and Borrowings         308,752,993         110,314,202           Repayment of Murabaha Loans and Borrowings         (228,819,186)         (216,536,016)           Finance Cost Paid         (24,276,678)         (27,973,310)           Dividend Paid         (257,222)         (112,418)           Net Change in Cash and Cash Equivalents<	Loss on sale of Property Plant and Equipment and Biological Assets	25,847,135	11,717,317
Changes in Inventory and Biological Assets - Available for Sale Biological Assets (10,727,508) 5,589,097 Trade Receivables, Prepayments and Other Receivables (222,250,242) (66,864,138) Trade and Other Payables 184,646,800 86,704,824 226,083,601 337,168,259 226,083,601 337,168,259 226,083,601 (265,505,428) (1,010,642) Employee Benefits Paid (26,505,428) (15,412,205) Net cash from Operating Activities 198,742,177 320,745,412 236,1610 of Property, Plant and Equipment, Intangible Assets and Biological Assets 59,100,302 40,527,075 Net cash Used in Investing Activities (208,463,841) (142,929,747) 26sh flows from Financing Activities (208,463,841) (142,929,747) 26sh flows from Investing Activities (208,463,841) (142,929,747) 27,075 Net cash Used in Investing Activities (208,463,841) (142,929,747) 28spyment of Murabaha Loans and Borrowings (228,819,186) (16,577) 28spyment of Murabaha Loans and Borrowings (228,819,186) (216,536,016) Finance Cost Paid (24,677,440) (41,561,577) 28yment of Lease Liabilities (24,286,678) (27,973,310) Dividend Paid (257,222) (112,418) Net cash from/ (Used in) Financing Activities (2990,803) 2,087,225 Cash and Cash Equivalents at beginning of the period (28,119,854) 66,2031,969 Cash and Cash Equivalents at end of the period (28,119,194)	Impairment losses on Property, Plant and Equipment		43,888,805
Inventory and Biological Assets - Available for Sale   (5,241,071)   (51,094,926)   Biological Assets   (10,727,508)   5,589,097   Trade Receivables, Prepayments and Other Receivables   (222,250,242)   (66,864,138)   184,646,800   86,704,824   226,083,601   337,168,259   (10,10,642)   Employee Benefits Paid   (835,996)   (1,010,642)   Employee Benefits Paid   (26,505,428)   (15,412,205)   Ret cash from Operating Activities   198,742,177   320,745,412   Cash flows from Investing Activities   198,742,177   320,745,412   Cash flows from Investing Activities   (267,564,143)   (183,456,822)   Assets   (267,564,143)   (183,456,822)   Assets   (208,463,841)   (142,929,747)   Cash flows from Financing Activities   (208,463,841)   (142,929,747)   Cash mode and Borrowings   (228,819,186)   (216,536,016)   Finance Cost Paid   (24,677,440)   (41,561,577)   Payment of Lease Liabilities   (24,286,678)   (27,973,310)   Dividend Paid   (257,222)   (112,418)   Net Cash from (Used in) Financing Activities   (209,90,803)   (208,7225)   Cash and Cash Equivalents   (209,90,803)   (208,7225)   Cash and Cash Equivalents at beginning of the period   (28,713,854)   (62,031,969)   Cash and Cash Equivalents at end of the period   (28,713,854)   (64,119,194)   (64,119,		279,655,622	362,833,402
Biological Assets   (10,727,508)   5,589,097   Trade Receivables, Prepayments and Other Receivables   (222,250,242)   (66,864,138)   Trade and Other Payables   184,646,800   86,704,824   226,083,601   337,168,259   (10,106,42)   Employee Benefits Paid   (26,505,428)   (15,412,205)   Net cash from Operating Activities   198,742,177   320,745,412   (15,412,205)   Net cash from Operating Activities   198,742,177   320,745,412   (183,456,822)   Assets   (267,564,143)   (183,456,822)   Assets   (267,564,143)   (183,456,822)   Assets   (208,463,841)   (142,929,747)   (23h flows from Financing Activities   (208,463,841)   (142,929,747)   (23h flows from Financing Activities   (208,463,841)   (142,929,747)   (228,819,186)   (216,536,016)   (24,677,440)   (41,561,577)   Asyment of Murabaha Loans and Borrowings   (228,819,186)   (216,536,016)   (24,677,440)   (41,561,577)   Asyment of Lease Liabilities   (24,286,678)   (27,973,310)   Dividend Paid   (24,677,440)   (41,561,577)   Asyment of Lease Liabilities   (24,286,678)   (27,973,310)   Dividend Paid   (24,677,440)   (41,561,577)   (41,561,			
Trade Receivables, Prepayments and Other Receivables  (222,250,042) (66,864,138)  Trade and Other Payables  (222,6083,601 337,168,259)  Zakat Paid (226,083,601 337,168,259)  Zakat Paid (835,996) (1,010,642)  Employee Benefits Paid (26,505,428) (15,412,205)  Net cash from Operating Activities  Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets  Acquisition of Property, Plant and Equipment and Biological Assets  Proceeds from sale of Property, Plant and Equipment and Biological Assets  Set (208,463,841) (142,929,747)  Cash flows from Financing Activities  Cash flows from Investing Activities  Proceeds from Suse of shares  Proceeds from Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  (228,819,186) (216,536,016)  Finance Cost Paid (24,677,440) (41,561,577)  Payment of Lease Liabilities  Dividend Paid  Net cash from/ (Used in) Financing Activities  Net Cash and Cash Equivalents  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period		(5,241,071)	(51,094,926)
Trade and Other Payables         184,646,800         86,704,824           Zakat Paid         226,083,601         337,168,259           Employee Benefits Paid         (26,505,428)         (1,010,642)           Met cash from Operating Activities         198,742,177         320,745,412           Cash flows from Investing Activities         198,742,177         320,745,412           Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets         (267,564,143)         (183,456,822)           Proceeds from sale of Property, Plant and Equipment and Biological Assets         59,100,302         40,527,075           Net cash Used in Investing Activities         (208,463,841)         (142,929,747)           Cash flows from Financing Activities         140,679           Proceeds from Murabaha Loans and Borrowings         308,752,993         110,314,202           Repayment of Murabaha Loans and Borrowings         (228,819,186)         (216,536,016)           Finance Cost Paid         (24,677,440)         (41,561,577)           Payment of Lease Liabilities         (24,286,678)         (27,973,310)           Dividend Paid         (24,286,678)         (27,973,310)           Net Change in Cash and Cash Equivalents         20,990,803         2,087,225           Cash and Cash Equivalents at end of the period         68,713,854		(10,727,508)	5,589,097
Zakat Paid         226,083,601         337,168,259           Employee Benefits Paid         (835,996)         (1,010,642)           Employee Benefits Paid         (26,505,428)         (15,412,205)           Net cash from Operating Activities         198,742,177         320,745,412           Cash flows from Investing Activities         (267,564,143)         (183,456,822)           Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets         59,100,302         40,527,075           Net cash Used in Investing Activities         (208,463,841)         (142,929,747)           Cash flows from Financing Activities         (208,463,841)         (142,929,747)           Cash flows from Investing Activities         140,679           Proceeds from Issue of shares         -         140,679           Proceeds from Murabaha Loans and Borrowings         308,752,993         110,314,202           Repayment of Murabaha Loans and Borrowings         (228,819,186)         (216,536,016)           Finance Cost Paid         (24,677,440)         (41,561,577)           Payment of Lease Liabilities         (24,286,678)         (27,973,310)           Dividend Paid         (24,286,678)         (27,973,310)           Net cash from/ (Used in) Financing Activities         30,712,467         (175,728,440)		(222,250,242)	(66,864,138)
Zakat Paid       (835,996)       (1,010,642)         Employee Benefits Paid       (26,505,428)       (15,412,205)         Net cash from Operating Activities       198,742,177       320,745,412         Cash flows from Investing Activities         Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets       (267,564,143)       (183,456,822)         Proceeds from sale of Property, Plant and Equipment and Biological Assets       59,100,302       40,527,075         Net cash Used in Investing Activities       (208,463,841)       (142,929,747)         Cash flows from Financing Activities       140,679         Proceeds from Issue of shares       140,679         Proceeds from Murabaha Loans and Borrowings       308,752,993       110,314,202         Repayment of Murabaha Loans and Borrowings       (228,819,186)       (216,536,016)         Finance Cost Paid       (24,286,678)       (27,973,310)         Poividend Paid       (24,286,678)       (27,973,310)         Net cash from/ (Used in) Financing Activities       30,712,467       (175,728,440)         Net Change in Cash and Cash Equivalents       20,990,803       2,087,225         Cash and Cash Equivalents at beginning of the period       68,713,854       62,031,969         Cash and Cash Equivalents at end of the period<	Trade and Other Payables	184,646,800	86,704,824
Zakat Paid       (835,996)       (1,010,642)         Employee Benefits Paid       (26,505,428)       (15,412,205)         Net cash from Operating Activities       198,742,177       320,745,412         Cash flows from Investing Activities         Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets       (267,564,143)       (183,456,822)         Proceeds from sale of Property, Plant and Equipment and Biological Assets       59,100,302       40,527,075         Net cash Used in Investing Activities       (208,463,841)       (142,929,747)         Cash flows from Financing Activities       140,679         Proceeds from Issue of shares       140,679         Proceeds from Murabaha Loans and Borrowings       308,752,993       110,314,202         Repayment of Murabaha Loans and Borrowings       (228,819,186)       (216,536,016)         Finance Cost Paid       (24,286,678)       (27,973,310)         Poividend Paid       (24,286,678)       (27,973,310)         Net cash from/ (Used in) Financing Activities       30,712,467       (175,728,440)         Net Change in Cash and Cash Equivalents       20,990,803       2,087,225         Cash and Cash Equivalents at beginning of the period       68,713,854       62,031,969         Cash and Cash Equivalents at end of the period<		226,083,601	337,168,259
Net cash from Operating Activities  Cash flows from Investing Activities  Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets  Proceeds from sale of Property, Plant and Equipment and Biological Assets  Proceeds from sale of Property, Plant and Equipment and Biological Assets  Proceeds from sale of Property, Plant and Equipment and Biological Assets  Seption 1 Investing Activities  Cash flows from Financing Activities  Proceeds from Issue of shares  Proceeds from Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  Finance Cost Paid  Finance Cost Paid  Payment of Lease Liabilities  Dividend Paid  Net cash from/ (Used in) Financing Activities  Net Change in Cash and Cash Equivalents  Cash and Cash Equivalents at beginning of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period			(1,010,642)
Net cash from Operating Activities  Cash flows from Investing Activities  Acquisition of Property, Plant and Equipment, Intangible Assets and Biological Assets  Proceeds from sale of Property, Plant and Equipment and Biological Assets  Proceeds from sale of Property, Plant and Equipment and Biological Assets  Net cash Used in Investing Activities  Cash flows from Financing Activities  Proceeds from Issue of shares  Proceeds from Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  Finance Cost Paid  Finance Cost Paid  Payment of Lease Liabilities  Dividend Paid  Net cash from/ (Used in) Financing Activities  Net Change in Cash and Cash Equivalents  Cash and Cash Equivalents at beginning of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period		(26,505,428)	(15,412,205)
Cash flows from Investing Activities(267,564,143)(183,456,822)Acquisition of Property, Plant and Equipment, Intangible Assets(267,564,143)(183,456,822)Proceeds from sale of Property, Plant and Equipment and Biological Assets59,100,30240,527,075Net cash Used in Investing Activities(208,463,841)(142,929,747)Cash flows from Financing Activities140,679Proceeds from Issue of shares140,679Proceeds from Murabaha Loans and Borrowings308,752,993110,314,202Repayment of Murabaha Loans and Borrowings(228,819,186)(216,536,016)Finance Cost Paid(24,677,440)(41,561,577)Payment of Lease Liabilities(24,286,678)(27,973,310)Dividend Paid(257,222)(112,418)Net cash from/ (Used in) Financing Activities30,712,467(175,728,440)Net Change in Cash and Cash Equivalents20,990,8032,087,225Cash and Cash Equivalents at beginning of the period68,713,85462,031,969Cash and Cash Equivalents at end of the period89,704,65764,119,194	Net cash from Operating Activities		
Assets Proceeds from sale of Property, Plant and Equipment and Biological Assets  Net cash Used in Investing Activities Cash flows from Financing Activities Proceeds from Issue of shares Proceeds from Murabaha Loans and Borrowings Repayment of Murabaha Loans and Borrowings Finance Cost Paid Payment of Lease Liabilities Dividend Paid Net cash from/ (Used in) Financing Activities Net Change in Cash and Cash Equivalents at beginning of the period Cash and Cash Equivalents at end of the period Cash and Cash Equivalents at end of the period  Proceeds from sale of Property, Plant and Equipment and Biological Assets 59,100,302 40,527,075 (208,463,841) (142,929,747) (142,929,747) (142,929,747) (142,929,747) (228,819,186) (228,819,186) (216,536,016) (24,286,678) (27,973,310) (257,222) (112,418) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440)			
Assets Proceeds from sale of Property, Plant and Equipment and Biological Assets  Net cash Used in Investing Activities Cash flows from Financing Activities Proceeds from Issue of shares Proceeds from Murabaha Loans and Borrowings Repayment of Murabaha Loans and Borrowings Finance Cost Paid Payment of Lease Liabilities Dividend Paid Net cash from/ (Used in) Financing Activities Net Change in Cash and Cash Equivalents at beginning of the period Cash and Cash Equivalents at end of the period Cash and Cash Equivalents at end of the period  Proceeds from sale of Property, Plant and Equipment and Biological Assets 59,100,302 40,527,075 (208,463,841) (142,929,747) (142,929,747) (142,929,747) (142,929,747) (228,819,186) (228,819,186) (216,536,016) (24,286,678) (27,973,310) (257,222) (112,418) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440) (175,728,440)	Acquisition of Property, Plant and Equipment, Intangible Assets and Biological	(nom no constant)	
Net cash Used in Investing Activities         (208,463,841)         (142,929,747)           Cash flows from Financing Activities         140,679           Proceeds from issue of shares         -         140,679           Proceeds from Murabaha Loans and Borrowings         308,752,993         110,314,202           Repayment of Murabaha Loans and Borrowings         (228,819,186)         (216,536,016)           Finance Cost Paid         (24,677,440)         (41,561,577)           Payment of Lease Liabilities         (24,286,678)         (27,973,310)           Dividend Paid         (257,222)         (112,418)           Net cash from/ (Used in) Financing Activities         30,712,467         (175,728,440)           Net Change in Cash and Cash Equivalents         20,990,803         2,087,225           Cash and Cash Equivalents at beginning of the period         68,713,854         62,031,969           Cash and Cash Equivalents at end of the period         89,704,657         64,119,194	Assets	(267,564,143)	(183,456,822)
Net cash Used in Investing Activities         (208,463,841)         (142,929,747)           Cash flows from Financing Activities         140,679           Proceeds from Issue of shares         140,679           Proceeds from Murabaha Loans and Borrowings         308,752,993         110,314,202           Repayment of Murabaha Loans and Borrowings         (228,819,186)         (216,536,016)           Finance Cost Paid         (24,677,440)         (41,561,577)           Payment of Lease Liabilities         (24,286,678)         (27,973,310)           Dividend Paid         (257,222)         (112,418)           Net cash from/ (Used in) Financing Activities         30,712,467         (175,728,440)           Net Change in Cash and Cash Equivalents         20,990,803         2,087,225           Cash and Cash Equivalents at beginning of the period         68,713,854         62,031,969           Cash and Cash Equivalents at end of the period         89,704,657         64,119,194	Proceeds from sale of Property, Plant and Equipment and Biological Assets	59,100,302	40,527,075
Cash flows from Financing Activities           Proceeds from Issue of shares         -         140,679           Proceeds from Murabaha Loans and Borrowings         308,752,993         110,314,202           Repayment of Murabaha Loans and Borrowings         (228,819,186)         (216,536,016)           Finance Cost Paid         (24,677,440)         (41,561,577)           Payment of Lease Liabilities         (24,286,678)         (27,973,310)           Dividend Paid         (257,222)         (112,418)           Net cash from/ (Used in) Financing Activities         30,712,467         (175,728,440)           Net Change in Cash and Cash Equivalents         20,990,803         2,087,225           Cash and Cash Equivalents at beginning of the period         68,713,854         62,031,969           Cash and Cash Equivalents at end of the period         89,704,657         64,119,194		(208,463,841)	(142,929,747)
Proceeds from Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  Repayment of Murabaha Loans and Borrowings  Finance Cost Paid  Payment of Lease Liabilities  (24,677,440)  (41,561,577)  Payment of Lease Liabilities  (24,286,678)  (27,973,310)  Dividend Paid  (257,222)  (112,418)  Net cash from/ (Used in) Financing Activities  Net Change in Cash and Cash Equivalents  20,990,803  2,087,225  Cash and Cash Equivalents at beginning of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  (41,561,577)  (24,286,678)  (27,973,310)  (175,728,440)  (175,728,440)  (257,222)  (112,418)  (257,222)  (12,418)  (26,031,969)  (27,973,310)  (27,973	Cash flows from Financing Activities		
Proceeds from Murabaha Loans and Borrowings       308,752,993       110,314,202         Repayment of Murabaha Loans and Borrowings       (228,819,186)       (216,536,016)         Finance Cost Paid       (24,677,440)       (41,561,577)         Payment of Lease Liabilities       (24,286,678)       (27,973,310)         Dividend Paid       (257,222)       (112,418)         Net cash from/ (Used in) Financing Activities       30,712,467       (175,728,440)         Net Change in Cash and Cash Equivalents       20,990,803       2,087,225         Cash and Cash Equivalents at beginning of the period       68,713,854       62,031,969         Cash and Cash Equivalents at end of the period       89,704,657       64,119,194	The state of the s	•	140.679
Repayment of Murabaha Loans and Borrowings       (228,819,186)       (216,536,016)         Finance Cost Paid       (24,677,440)       (41,561,577)         Payment of Lease Liabilities       (24,286,678)       (27,973,310)         Dividend Paid       (257,222)       (112,418)         Net cash from/ (Used in) Financing Activities       30,712,467       (175,728,440)         Net Change in Cash and Cash Equivalents       20,990,803       2,087,225         Cash and Cash Equivalents at beginning of the period       68,713,854       62,031,969         Cash and Cash Equivalents at end of the period       89,704,657       64,119,194		308,752,993	· ·
Finance Cost Paid (24,677,440) (41,561,577)  Payment of Lease Liabilities (24,286,678) (27,973,310)  Dividend Paid (257,222) (112,418)  Net cash from/ (Used in) Financing Activities 30,712,467 (175,728,440)  Net Change in Cash and Cash Equivalents 20,990,803 2,087,225  Cash and Cash Equivalents at beginning of the period 68,713,854 62,031,969  Cash and Cash Equivalents at end of the period 89,704,657 64,119,194	Repayment of Murabaha Loans and Borrowings	· ·	
Payment of Lease Liabilities       (24,286,678)       (27,973,310)         Dividend Paid       (257,222)       (112,418)         Net cash from/ (Used in) Financing Activities       30,712,467       (175,728,440)         Net Change in Cash and Cash Equivalents       20,990,803       2,087,225         Cash and Cash Equivalents at beginning of the period       68,713,854       62,031,969         Cash and Cash Equivalents at end of the period       89,704,657       64,119,194	Finance Cost Paid	(24,677,440)	
Dividend Paid         (257,222)         (112,418)           Net cash from/ (Used in) Financing Activities         30,712,467         (175,728,440)           Net Change in Cash and Cash Equivalents         20,990,803         2,087,225           Cash and Cash Equivalents at beginning of the period         68,713,854         62,031,969           Cash and Cash Equivalents at end of the period         89,704,657         64,119,194	Payment of Lease Liabilities		
Net cash from/ (Used in) Financing Activities         30,712,467         (175,728,440)           Net Change in Cash and Cash Equivalents         20,990,803         2,087,225           Cash and Cash Equivalents at beginning of the period         68,713,854         62,031,969           Cash and Cash Equivalents at end of the period         89,704,657         64,119,194	Dividend Paid		
Net Change in Cash and Cash Equivalents  Cash and Cash Equivalents at beginning of the period  Cash and Cash Equivalents at end of the period  Cash and Cash Equivalents at end of the period  Reprivation 1.10  R	Net cash from/ (Used in) Financing Activities		
Cash and Cash Equivalents at beginning of the period  Cash and Cash Equivalents at end of the period  68,713,854  62,031,969  64,119,194			
Cash and Cash Equivalents at end of the period 89,704,657 64.119.194			
		Idenced interim financial at	U-1,113,134

The accompanying notes 1 to 12 are an integral part of these condensed interim financial statements

The condensed interim financial statements appearing on pages 3 to 14 were approved by the Board of Directors and were

signed by the behalf by

Asimakopoulos Georgios Chief Financial Officer Steen Hadsbjerg Chief Executive Officer



#### 1- The Company and its Operations

The National Agricultural Development Company (NADEC) (the "Company") is a Saudi Joint-Stock Company, formed under the Royal Decree No. M/41 dated 17 Shawwal 1401H (corresponding to 17 August 1981) and registered in Riyadh under Commercial Registration No. 1010018795 dated 26 Dhul-Hijjah 1398H (corresponding to 26 November 1978).

The Company is engaged in agricultural and livestock production, reclamation of agricultural land, food processing and marketing and distribution of its products.

The Company's financial year begins on January 1 and ends at the end of December of the same year.

The Company's registered office is located at the following address:

Riyadh - Kingdom of Saudi Arabia

P.O. Box 2557 Riyadh 11461

#### 2- Basis of Preparation

#### 2.1 Statement of Compliance

These Condensed Interim Financial Statements of the Company have been prepared in accordance with the requirements of the International Accounting Standard-IAS 34 - "Interim Financial Reporting" that is endorsed in the Kingdom of Saudi Arabia (KSA) and other standards and pronouncements that are issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA").

These Condensed Interim Financial Statements should be read in conjunction with the Financial Statements of the Company for the year ended 31 December 2020 (last annual financial statements). They do not include all the information required to present a complete set of financial statements prepared in accordance with International Financial Reporting Standards (IFRS) that are endorsed in the KSA. However, accounting policies and specific explanatory notes have been included to interpret significant events and transactions in order to understand the changes in the financial position and financial performance of the Company, since the last annual financial statements.

#### 2.2 Basis of Measurement

These Condensed Interim Financial Statements have been prepared in accordance with historical cost except for the following significant items included in the Condensed Interim Statement of Financial Position:

- Equity Investment at FVOCI is valued at fair value in accordance with the requirements of IFRS 13 using level 2 valuation method.
- Biological Assets for which market is available or can be measured reliably are valued at Fair value, where fair value is not
  available or cannot be measured reliably, these assets are measured at cost.
- Derivative financial instruments are measured at Fair Value through Profit or Loss.
- Employee defined benefit obligations are recognized at the present value using Projected Unit Credit method.

#### 2.3 Functional and Presentation Currency

These Condensed Interim Financial Statements have been presented in Saudi Riyal ("SAR") which is also the functional currency of the Company, unless stated otherwise.

#### 2.4 SIGNIFICANT ACCOUNTING POLICIES

#### New Standards, Amendment to Standards and Interpretations:

There are no new standards issued, however, there are number of amendments to standards which are effective from 1 January 2021 and has been explained in Company's annual Financial Statements, but they do not have a material effect on the Company's Condensed Interim Financial Statements.



#### 3- Significant Accounting Estimates, Judgements and Assumptions

The preparation of the Company's condensed interim Financial Statements requires management to make judgments, estimates and assumptions that affect the reported amounts of Revenues, Expenses, Assets and Liabilities, and the accompanying Disclosures, and the disclosure of Contingent Liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.

The key assumptions concerning the future and other key sources of estimation, uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial years, are consistent with those disclosed in the last annual financial statements. The Company based its assumptions and estimates on parameters available when the Financial Statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Company. Such changes are reflected in the assumptions when they occur. The significant judgments made by management in applying the Company's accounting policies are consistent with those disclosed in the last annual financial statements.

In response to the spread of the Covid-19 in territories where the Company operates and its resulting disruptions to the social and economic activities in those markets, NADEC's management proactively assessed its impacts on its operations and took a series of preventive measures, including the creation of Corona task force team, to ensure the health and safety of its employees, customers, consumers and wider community as well as to ensure the continuity of supply of its products throughout its markets. NADEC's business operations largely remained unaffected as the food industry in general was exempted from various bans and restrictions imposed by various regulatory authorities. Accordingly, the Covid-19 pandemic has had no material effects on NADEC's reported financial results for the nine month period ended 30 September 2021. Also, as the restrictions of COVID 19 eases out and the vaccination rate is increasing, NADEC's management does not foresee any negative impacts on the Company in the foreseeable future arising from COVID 19.



#### 4. Operating Segments

IFRS 8 requires operating segments to be identified based on internal reports that are regularly reviewed by the Company's executive management and used to allocate resources to segments and assess their performance. The operating segments described below have been prepared in accordance with IFRS 8. The Company operates in two main business segments: Manufacturing of Dairy and foods and Production of Agricultural products. Most of the Company's revenues, profits and assets relate to its operations in Saudi Arabia and arise from these reportable operating segments. The executive management monitors the operational results of these operating segments separately for making decisions about resource allocation and performance evaluation. The performance of the segment is evaluated on a profit or loss basis and is measured in a manner consistent with the profit or loss recognized in the Condensed Interim Financial Statements.

The following is a summary of the operating segments as at and for the nine month period ended 30 September 2021

	Dairy and Food	Agriculture	(Elimination of Inter-Segment Sales)/ unallocated	Total
	SAR	SAR	SAR	SAR
Revenue				
External Revenue	1,601,463,223	63,629,489	-	1,665,092,712
Inter-Segment Revenue	19,437,500	54,040,252	(73,477,752)	<del></del>
Total	1,620,900,723	117,669,741	(73,477,752)	1,665,092,712
Expenses	8		-	***************************************
Depreciation and Amortization	(184,325,229)	(19,035,155)	-	(203,360,384)
Operating Profit/(Loss)	72,749,827	(55,691,925)	4,500,000	21,557,902
Finance Cost	(24,799,763)		-	(24,799,763)
Profit / (Loss) before Zakat	47,950,064	(55,691,925)	4,500,000	(3,241,861)
Zakat	(4,500,000)	(28,003)	-	(4,528,003)
Profit/ (Loss) for the Period	43,450,064	(55,719,928)	4,500,000	(7,769,864)
Total Assets	3,524,873,828	615,023,587	-	4,139,897,415

The following is a summary of the operating segments as at and for the nine month period ended 30 September 2020

the following is a summary of the operating		ре	(Elimination of	2020
	Dairy and Food	Agriculture	Inter-Segment Sales)/ unallocated	Total
	SAR	SAR	SAR	SAR
Revenue				
External Revenue	1,644,456,509	109,983,567	-	1,754,440,076
Inter-Segment Revenue	15,080,800	42,877,683	(57,958,483)	
Total	1,659,537,309	152,861,250	(57,958,483)	1,754,440,076
Expenses		-		
Depreciation and Amortization	(190,884,928)	(29,422,419)		(220,307,347)
Operating Profit	103,506,865	39,624,585	-	143,131,450
Finance Cost	(33,084,259)	(1,158,754)	-	(34,243,013)
Gain on Derivative financial Instruments	<u> </u>	_	353,193	353,193
Profit before Zakat	70,422,606	38,465,831	353,193	109,241,630
Zakat	(4,050,000)	(271,839)	-	(4,321,839)
Profit for the Period	66,372,606	38,193,992	353,193	104,919,791
Total Assets	3,269,566,796	743,217,929		4,012,784,725



#### 5. Earnings per Share

	Three month period ended 30 Sep 2021 SAR (Unaudited)	Three month period ended 30 Sep 2020 SAR (Unaudited)	Nine month period ended 30 Sep 2021 SAR (Unaudited)	Nine month period ended 30 Sep 2020 SAR (Unaudited)
Profit/ (Loss) attributable to Shareholders' (Saudi Riyal -SAR)	3,214,000	(44,893,915)	(7,769,864)	104,919,791
Weighted Average Number of Ordinary Shares (# of Shares)	101,640,000	101,640,000	101,640,000	101,636,585
Earnings/ (Loss) perShare (SAR/Share)	0.03	(0.44)	(0.08)	1.03

Earnings/ (Loss) per share has been calculated by dividing profit/ (loss) attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period.

#### 6. Share Capital

	30 Sep 21	31 Dec 20
Capital	(Unaudited)	(Audited)
Ordinary Shares issued and fully paid of SAR 10 each	101,640,000	101,640,000

#### 7. Murabaha Loans and Borrowings

	Loan Currency	Interest rate	Due date	30 Se (Unau	p 21 dited)	31 De (Aud	ec 20 ited)
				Nominal Value SAR'M	Book value SAR'M	Nominal Value SAR 'M	Book value SAR'M
		SIBOR+					
Islamic Banking Facilities (7.1)	SAR	Bank Margin*	2021-2028	1,559	1,563	1,478	1,484
Agricultural Development Fund (7.2)	SAR	-	2021-2027	6	6	7	7
				1,565	1,569	1,485	1,491

<sup>\*</sup>The weighted average interest rate on bank loans during the nine month period ended 30 September 2021 was 2.02% per annum (Nine month period ended 30 September 2020: 3.00% per annum), however, the rates varied between medium and short-term loans.

- Loans from local banks were granted against promissory note given by the Company.

Loans are presented in the Condensed Interim Financial Statements as follows:

	30 Sep 21 SAR 'M	31 Dec 20 SAR'M
	(Unaudited)	(Audited)
Non-Current Liabilities	) <del></del>	
Loans secured by guarantees	5	6
Loans secured by promissory notes	1,145_	875
	1,150	881
Current Liabilities	<del> </del>	
Loans secured by guarantees	1	1
Loans secured by promissory notes	418	609
	419	610



#### 7. Murabaha Loansand Borrowings (Continued)

#### 7.1 Islamic Banking Facilities (Murabaha) from Local Banks

The borrowing under Islamic banking facilities (Murabaha) have been provided against a promissory note issued by the Company. The maturity dates of these facilities are from 2021 to 2028 as agreed with the respective banks and are mostly of a revolving nature. The amount of unused facilities as at 30 September 2021 amounted to SAR 724 Million. (31 December 2020: SAR 608 Million).

#### 7.2 Agricultural Development Fund Loan

The Company was granted two loans from the Agricultural Development Fund with a total value of SAR 9.95 million. These loans are secured by a mortgage of specific assets owned by the Company. The maturity dates of these facilities are from 2024 to 2027 as agreed with the Agricultural Development Fund. The balance of these loans from Agricultural Development Fund on 30 September 2021 amounted to SAR 5.5 million (31 December 2020: SAR 7.4 million).

#### 8. Revenue

	Nine month period ended 30	Nine months period ended
	Sep 2021	30 Sep 2021
	SAR	SAR
	(Unaudited)	(Unaudited)
Saudi Arabia	1,491,682,295	1,559,118,682
Other Countries	173,410,417	195,321,394
	1,665,092,712	1,754,440,076

The main sources of the Company's revenues from contracts with customers includes dairy and food sales as well as the agricultural products, calves' sales and others. The control of the products is transferred to the customer as soon as it is delivered to them and the delivery has been acknowledged.

#### 9. Property, Plant and Equipment

The carrying amount of Property, Plant and Equipment as at 30 Sept 2021 amounted to SAR 1.89 Billion (31 December 2020: SAR 1.96 Billion). During the nine month period ended 30 September 2021, the Company added Property, Plant and Equipment amounting to SAR 73 Million (Nine month period ended 30 September 2020: SAR 58 Million).

#### 9.1 Lands

The following matters related to Lands held by the Company at the reporting date:

Land granted to the Company by the Government awaiting transfer of legal title (Carrying value of land is SAR 198.67 million)

As at 30 September 2021, the Company held SAR198.67 million worth of land received from the Government awaiting transfer of legal titles for which the conditions of the grant had been met in earlier years.

The details of the land and government grant are as follows:

- The Company originally received certain area of land in Hail, Wadi Al Dawasir and Al Jouf as a conditional non-monetary grant
  under the Ministry of Environment, Water and Agriculture under the Royal Order M/41 issued on 17 Shawwal 1401H
  (corresponding to 17 August 1981) hereinafter referred to as "Royal Order of 1981" which stated that the Company will be
  entitled to the ownership of the land which is revived by the Company. Until 31 March 2020, the Company had recognized
  portion of these lands at a value of SAR 120.86 million for which the conditions of the grant were met.
- On 2 Dhul-Qadah 1441H (corresponding to 23 June 2020), the Company received a letter from Ministry of Environment, Water and Agriculture under number 600/1057/1438 regarding issuance of Royal Order No. 58378 dated 28 Shawwal 1441H (corresponding to 20 June 2020) hereinafter referred to as "Royal Order of 2020" confirming the area to which Company is entitled.
- Based on the Royal Order of 2020, the Company has recorded the additional land granted for Al Jouf and Wadi Al Dawasir at
  its current fair value and has derecognized the unconfirmed land area of Hail from the books which has resulted in a net gain
  of SAR 111.8 million and have increased the carrying value of land to SAR 232.67 million during the year 2020.



#### 9. Property, Plant and Equipment - (Continued)

#### 9.1 Land-(Continued)

#### Land granted to the Company by the Government awaiting transfer of legal title (Continued)

During the current quarter the Company received the legal titles of land in Wadi Al Dawasir and the management is reasonably
certain that the legal title of remaining lands will be transferred to the Company in due course upon completion of the
regulatory procedures.

#### Land Occupied by Saudi Aramco

As per the Royal Decree number (151) dated 5 Shawwal 1401H (corresponding to 5 August 1981), NADEC was granted the Haradh project. This included a piece of agricultural land, fixed and movable facilities and assets as well as the energy sources being part of the site. Notary Public at Haradh issued land title deed to NADEC through title deed number (333801001781).

The Supreme Court cancelled the land title deed issued to the NADEC by Notary Public at Haradh through its decision dated 18 Rabi ul Awal 1442H (corresponding to 4 November 2020), with an understanding of reissuing the title deed for the area occupied by NADEC and is under NADEC's use.

Based on discussions with the officials of Ministry of environment, water, and agriculture, management is reasonably certain that the legal title of this land under NADEC's use and control will be issued to the NADEC after obtaining all the necessary approvals from related government authorities. Consequently, the new title deed will result in reduction of NADEC's assets, due to removal of a limited portion of the land, which is currently being occupied by ARAMCO and a small piece of land in the southern area which is not suitable for agricultural production and consequently is not being used by NADEC.

The financial Impact of the change in land area is not ascertainable as at the reporting date in the absence of definitive court order however management estimates that the impact will not be material.

#### 10. Prepayments

Increase in prepayments during the current period is mainly on account of increase in purchases during the period.



#### 11. Financial Instruments

Financial Assets and Liabilities are measured at amortized cost except for Equity Investments at Fair value through Other Comprehensive Income (FVOCI) which are measured at fair value. The fair value is the price that would be received to self an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under market conditions. In the absence of an active market, the asset or liability is measured in the most advantageous market for the asset or liability and relies on the perceptions of market participants to maximize the benefits of using the asset. The Company relied on valuation methods for Equity Investments at FVOCI based on the performance of similar financial assets in an active market considering the performance of the asset itself to maximize benefits from the asset.

The book value and the fair value of all financial assets and financial liabilities does not vary significantly.

Financial Assets at Fair Value	30 Sep 21 SAR'000 (Unaudited)	31 Dec 20 SAR'000 (Audited)	FV level
Equity Investment at FVOCI	7,629	7,629	Level 2
Total Financial Assets at Fair Value	7,629	7,629	
Financial Assets at Amortized Cost			
Trade and Other Receivables	293,771	286,753	
Cash and Bank Balances	89,704	68,714	
Total Financial Assets at Amortized Cost	383,475	355,467	
Total Financial Assets	391,104	363,096	
Financial Liabilities at Amortized Cost			
Trade and Other Payables	764,061	589,088	
Loans	1,568,744	1,490,733	
Lease Liabilities	74,189	62,759	
Total Financial Liabilities at Amortized Cost	2,406,994	2,142,580	
Total Financial Liabilities	2,406,994	2,142,580	

#### 12. Approval by the Board of Directors

These Condensed Interim Financial Statements for the nine months period ended 30 September 2021 were approved by the Board of Directors on 15 Rabi ul Awal 1443 H (corresponding to 21 October 2021).